These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 4082104)

  • 1. Drug-related changes in platelet shape in whole blood.
    Rosenstein R
    Thromb Res; 1985 Sep; 39(5):613-8. PubMed ID: 4082104
    [No Abstract]   [Full Text] [Related]  

  • 2. Status of antiplatelet drugs in coronary heart disease.
    Mehta J; Mehta P
    JAMA; 1979 Jun; 241(24):2649-51. PubMed ID: 439365
    [No Abstract]   [Full Text] [Related]  

  • 3. Platelet release and aggregation induced by antithymocyte globulin. In vitro effect of inhibitors.
    Rosenberg JC; Sell T
    Transplantation; 1975 Oct; 20(4):346-50. PubMed ID: 169611
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of very low versus standard dose acetyl salicylic acid, dipyridamole and sulfinpyrazone on platelet function and thromboxane formation in man.
    Lorenz R; Siess W; Weber PC
    Eur J Pharmacol; 1981 Apr; 70(4):511-8. PubMed ID: 7238575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of antiplatelet drugs and clinical trials on thrombosis prevention: a difficult link.
    de Gaetano G; Cerletti C; Bertelè V
    Lancet; 1982 Oct; 2(8305):974-7. PubMed ID: 6127469
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of sulphinpyrazone and dipyridamole on capillary bleeding time in man.
    Weston MJ; Rubin MH; Langley PG; Westaby S; Williams R
    Thromb Res; 1977 Jun; 10(6):833-40. PubMed ID: 882967
    [No Abstract]   [Full Text] [Related]  

  • 7. [Influence of platelet aggregation inhibitors on platelet damage at prosthetic heart valves in-vitro (author's transl)].
    Häussinger G; Pfennigs H; Chelapurath A; Reul H; Essers U
    Biomed Tech (Berl); 1981 May; 26(5):99-102. PubMed ID: 6788103
    [No Abstract]   [Full Text] [Related]  

  • 8. Antiplatelet therapy.
    Sloan RW
    Am Fam Physician; 1981 Oct; 24(4):129-34. PubMed ID: 7025599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelets and prostaglandins in coronary artery disease. Rationale for use of platelet-suppressive drugs.
    Mehta J
    JAMA; 1983 May; 249(20):2818-23. PubMed ID: 6341645
    [No Abstract]   [Full Text] [Related]  

  • 10. Proceedings: Comparison of in vivo and in vitro effects of platelet function suppressing drugs.
    Buchanan M; Hirsh J
    Thromb Diath Haemorrh; 1975 Nov; 34(2):552. PubMed ID: 1198423
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of acetylsalicylic acid, sulfinpyrazone and dipyridamole on platelet adhesion and aggregation in flowing native and anticoagulated blood.
    Baumgartner HR
    Haemostasis; 1979; 8(3-5):340-52. PubMed ID: 511014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antiplatelet drugs (author's transl)].
    Dechavanne M; Follea G; Trzeciak MC
    Anesth Analg (Paris); 1979; 36(7-8):283-7. PubMed ID: 525834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex vivo and in vivo evaluation of drugs that inhibit platelet function.
    Hanson SR; Harker LA
    Ann N Y Acad Sci; 1983; 416():642-50. PubMed ID: 6587821
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of platelets in thrombotic and vascular disease.
    Schafer AI; Handin RI
    Prog Cardiovasc Dis; 1979; 22(1):31-52. PubMed ID: 379914
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of drugs of platelets and complications of vascular disease.
    Mustard JF; Packham MA; Kinlough-Rathbone RL
    Adv Exp Med Biol; 1977; 82():94-105. PubMed ID: 920448
    [No Abstract]   [Full Text] [Related]  

  • 16. Human equivalent doses of platelet inhibitors and experimental atherosclerosis.
    Mittal SR; Mathur AK; Tandon R
    Int J Cardiol; 1990 May; 27(2):275-6. PubMed ID: 2365516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition.
    Hanson SR; Harker LA; Bjornsson TD
    J Clin Invest; 1985 May; 75(5):1591-9. PubMed ID: 3923041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of platelet function inhibitors on experimental venous thrombosis formation in rabbits.
    Arfors KE; Bergqvist D; Tangen O
    Acta Chir Scand; 1975; 141(1):40-2. PubMed ID: 1092111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet therapy (first of two parts).
    Weiss HJ
    N Engl J Med; 1978 Jun; 298(24):1344-7. PubMed ID: 651993
    [No Abstract]   [Full Text] [Related]  

  • 20. Modulation of the inhibitory action of prostaglandin E1 on platelet aggregation in rats: a study with ticlopidine, aspirin, dipyridamole and sulfinpyrazone.
    Tuong CC; Ferrand C; Aubert D; Loubrie JC; Tuong A
    Biochem Pharmacol; 1982 Mar; 31(6):1147-50. PubMed ID: 7200772
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.